Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Lymphangioleiomyomatosis (LAMP-2)
NCT06889168Phase 1Recruiting
- Sponsor
- Columbia University
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in lymphangioleiomyomatosis (LAM) comparing Imatinib Mesylate Group with Placebo Group (2 arms). Primary endpoint: Incidence of Adverse Events at 1 year. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT06889168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889168.